Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hikma Gets $535m Off BI's Roxane Over Rebate Discrepancy

This article was originally published in Scrip

Executive Summary

"A very good deal that just got a little sweeter," is how Hikma CEO Said Darwazah described the $535m purchase price reduction of Roxane Laboratories Inc. from Boehringer Ingelheim. The discount was result of "new information" from BI in relation to Roxane's financial performance in 2015, specifically higher than expected rebates offered by Roxane.


Related Content

Hikma Hit By Approval Delays, But Advair Diskus Generic Expected Next Year





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts